Treatment with an Interleukin 1 beta antibody improves glycemic control in diet-induced obesity

O. Osborn, Sara Brownell, M. Sanchez-Alavez, D. Salomon, H. Gram, T. Bartfai

Research output: Contribution to journalArticle

98 Citations (Scopus)

Abstract

The proinflammatory cytokine Interleukin 1 beta (IL-1β) is elevated in obese individuals and rodents and it is implicated in impaired insulin secretion, decreased cell proliferation and apoptosis of pancreatic beta cells. In this study we describe the therapeutic effects by an IL-1β antibody to improve glucose control in hyperglycemic mice with diet-induced obesity. After 13 weeks of treatment the IL-1β antibody treated group showed reduced glycated hemoglobin (*P = 0.049), reduced serum levels of proinsulin (*P = 0.015), reduced levels of insulin and smaller islet size (*P = 1.65E-13) relative to the control antibody treated group. Neutralization of IL-1β also significantly reduced serum amyloid A (SAA) which is an indicator of inflammation-induced acute phase response (*P = 0.024). While there was no improvement of obesity, a significant improvement of glycemic control and of beta cell function is achieved by this pharmacological treatment which may slow/prevent disease progression in Type 2 Diabetes.

Original languageEnglish (US)
Pages (from-to)141-148
Number of pages8
JournalCytokine
Volume44
Issue number1
DOIs
StatePublished - Oct 2008
Externally publishedYes

Fingerprint

Nutrition
Interleukin-1beta
Obesity
Diet
Antibodies
Insulin
Serum Amyloid A Protein
Proinsulin
Obese Mice
Acute-Phase Reaction
Glycosylated Hemoglobin A
Cell proliferation
Insulin-Secreting Cells
Therapeutic Uses
Medical problems
Type 2 Diabetes Mellitus
Disease Progression
Rodentia
Cell Proliferation
Pharmacology

Keywords

  • Diabetes
  • Hyperglycemia
  • Interleukin 1 alpha
  • Interleukin 1 beta
  • Obesity

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Hematology
  • Biochemistry
  • Molecular Biology

Cite this

Treatment with an Interleukin 1 beta antibody improves glycemic control in diet-induced obesity. / Osborn, O.; Brownell, Sara; Sanchez-Alavez, M.; Salomon, D.; Gram, H.; Bartfai, T.

In: Cytokine, Vol. 44, No. 1, 10.2008, p. 141-148.

Research output: Contribution to journalArticle

Osborn, O. ; Brownell, Sara ; Sanchez-Alavez, M. ; Salomon, D. ; Gram, H. ; Bartfai, T. / Treatment with an Interleukin 1 beta antibody improves glycemic control in diet-induced obesity. In: Cytokine. 2008 ; Vol. 44, No. 1. pp. 141-148.
@article{e37ea0284d84458d873978ac323701ee,
title = "Treatment with an Interleukin 1 beta antibody improves glycemic control in diet-induced obesity",
abstract = "The proinflammatory cytokine Interleukin 1 beta (IL-1β) is elevated in obese individuals and rodents and it is implicated in impaired insulin secretion, decreased cell proliferation and apoptosis of pancreatic beta cells. In this study we describe the therapeutic effects by an IL-1β antibody to improve glucose control in hyperglycemic mice with diet-induced obesity. After 13 weeks of treatment the IL-1β antibody treated group showed reduced glycated hemoglobin (*P = 0.049), reduced serum levels of proinsulin (*P = 0.015), reduced levels of insulin and smaller islet size (*P = 1.65E-13) relative to the control antibody treated group. Neutralization of IL-1β also significantly reduced serum amyloid A (SAA) which is an indicator of inflammation-induced acute phase response (*P = 0.024). While there was no improvement of obesity, a significant improvement of glycemic control and of beta cell function is achieved by this pharmacological treatment which may slow/prevent disease progression in Type 2 Diabetes.",
keywords = "Diabetes, Hyperglycemia, Interleukin 1 alpha, Interleukin 1 beta, Obesity",
author = "O. Osborn and Sara Brownell and M. Sanchez-Alavez and D. Salomon and H. Gram and T. Bartfai",
year = "2008",
month = "10",
doi = "10.1016/j.cyto.2008.07.004",
language = "English (US)",
volume = "44",
pages = "141--148",
journal = "Cytokine",
issn = "1043-4666",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Treatment with an Interleukin 1 beta antibody improves glycemic control in diet-induced obesity

AU - Osborn, O.

AU - Brownell, Sara

AU - Sanchez-Alavez, M.

AU - Salomon, D.

AU - Gram, H.

AU - Bartfai, T.

PY - 2008/10

Y1 - 2008/10

N2 - The proinflammatory cytokine Interleukin 1 beta (IL-1β) is elevated in obese individuals and rodents and it is implicated in impaired insulin secretion, decreased cell proliferation and apoptosis of pancreatic beta cells. In this study we describe the therapeutic effects by an IL-1β antibody to improve glucose control in hyperglycemic mice with diet-induced obesity. After 13 weeks of treatment the IL-1β antibody treated group showed reduced glycated hemoglobin (*P = 0.049), reduced serum levels of proinsulin (*P = 0.015), reduced levels of insulin and smaller islet size (*P = 1.65E-13) relative to the control antibody treated group. Neutralization of IL-1β also significantly reduced serum amyloid A (SAA) which is an indicator of inflammation-induced acute phase response (*P = 0.024). While there was no improvement of obesity, a significant improvement of glycemic control and of beta cell function is achieved by this pharmacological treatment which may slow/prevent disease progression in Type 2 Diabetes.

AB - The proinflammatory cytokine Interleukin 1 beta (IL-1β) is elevated in obese individuals and rodents and it is implicated in impaired insulin secretion, decreased cell proliferation and apoptosis of pancreatic beta cells. In this study we describe the therapeutic effects by an IL-1β antibody to improve glucose control in hyperglycemic mice with diet-induced obesity. After 13 weeks of treatment the IL-1β antibody treated group showed reduced glycated hemoglobin (*P = 0.049), reduced serum levels of proinsulin (*P = 0.015), reduced levels of insulin and smaller islet size (*P = 1.65E-13) relative to the control antibody treated group. Neutralization of IL-1β also significantly reduced serum amyloid A (SAA) which is an indicator of inflammation-induced acute phase response (*P = 0.024). While there was no improvement of obesity, a significant improvement of glycemic control and of beta cell function is achieved by this pharmacological treatment which may slow/prevent disease progression in Type 2 Diabetes.

KW - Diabetes

KW - Hyperglycemia

KW - Interleukin 1 alpha

KW - Interleukin 1 beta

KW - Obesity

UR - http://www.scopus.com/inward/record.url?scp=52949129811&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=52949129811&partnerID=8YFLogxK

U2 - 10.1016/j.cyto.2008.07.004

DO - 10.1016/j.cyto.2008.07.004

M3 - Article

VL - 44

SP - 141

EP - 148

JO - Cytokine

JF - Cytokine

SN - 1043-4666

IS - 1

ER -